Medical Condition News

RSS

CPEX Pharmaceuticals to feature Nasulin at the Diabetes Technology Meeting

CPEX Pharmaceuticals, Inc. today announced that its intranasal insulin product candidate, NasulinTM, will be featured in an oral presentation and four abstracts at the Ninth Annual Diabetes Technology Meeting, November 5-7, 2009 at the Hyatt Regency Airport in San Francisco, California.

6 Nov 2009

Gene therapy saves two children with adrenoleukodystrophy

The ELA association and Zinedine Zidane, its emblematic ambassador, are proud to announce a world premiere: the results regaring the gene therapy in adrenoleukodystrophy conducted in France have just been published in the prestigious journal Science. Two children have been treated and their diseases have been halted. The children are doing well, which is unexpected for a disease destroying the brain in a few months. This discovery opens up treatment perspectives for numerous widespread diseases.

6 Nov 2009

Physical education plays a key role for low-income communities in curbing obesity and improving fitness

School-based physical education plays a key role in curbing obesity and improving fitness among adolescents from low-income communities, according to a new study led by researchers at the University of California, San Francisco and UC Berkeley.

6 Nov 2009

Autism Consortium holds its fourth annual symposium to update on autism

The Autism Consortium, an innovative collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), held its fourth annual symposium on October 28th, 2009, at Harvard Medical School in Boston.

6 Nov 2009

Boosting NAD+ after spinal cord injury may prevent permanent nerve death

Substances naturally produced by the human body may one day help prevent paralysis following a spinal cord injury, according to researchers at Weill Cornell Medical College. A recent $2.5 million grant from the New York State Spinal Cord Injury Research Board will fund their research investigating this possibility.

6 Nov 2009

TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

Cephalon, Inc. today announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab.

6 Nov 2009

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.

6 Nov 2009

Successful leukemia treatment with a radiolabeled antibody followed by stem cell transplant

For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options.

6 Nov 2009

Soda and other sugar-sweetened beverages linked to obesity; soda industry fails to acquit itself in landmark hearings

In today’s landmark hearings called by State Senators Alex Padilla (D-Pacoima) and Elaine Kontominas Alquist (D-San Jose), representatives from the soda industry failed to acquit themselves of a growing body of research implicating sugar-sweetened beverages as the leading culprit in the obesity epidemic.

6 Nov 2009

Revised Management Guidelines for diagnosing and treating thyroid cancer released

The American Thyroid Association has released new, revised Management Guidelines for the diagnosis and treatment of patients with thyroid nodules and thyroid cancer. The new guidelines are published in Thyroid, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com).

6 Nov 2009

AcuFocus Corneal Inlay: Will it improve near vision in patients with presbyopia?

The Cornea and Laser Eye Institute is participating in a research study to determine if an investigational corneal inlay can safely and effectively reduce the need for reading glasses. Dr. Peter Hersh, the study doctor, will perform the procedures.

6 Nov 2009

Declining kidney function linked to higher risk of heart failure in individuals with or without kidney disease

Declining kidney function is linked to a higher risk of heart failure, heart attack, peripheral arterial disease, and early death in individuals with or without kidney disease, according to a pair of studies appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

6 Nov 2009

Exposure to higher levels of air pollution increases infants' risk for bronchiolitis

Infants who are exposed to higher levels of air pollution are at increased risk for bronchiolitis, according to a new study.

6 Nov 2009

Prevalence of lactose intolerance may be far lower than previously estimated, says study

Prevalence of lactose intolerance may be far lower than previously estimated, according to a study in the latest issue of Nutrition Today. The study, which uses data from a national sample of three ethnic groups, reveals that the overall prevalence rate of self-reported lactose intolerance is 12 percent - with 7.72 percent of European Americans, 10.05 percent of Hispanic Americans and 19.5 percent of African Americans who consider themselves lactose intolerant.

6 Nov 2009

Higher levels of phosphorus in blood linked to increased calcification of coronary arteries, says study

Higher levels of phosphorus in the blood are linked to increased calcification of the coronary arteries— a key marker of heart disease risk, according to a study in an upcoming issue of Clinical Journal of the American Society of Nephrology (CJASN). "This may help to explain why even early-stage chronic kidney disease (CKD) is associated with increased cardiovascular risk that is not otherwise explained by traditional risk factors," comments Katherine R. Tuttle, MD (Providence Medical Research Center, Spokane, WA).

6 Nov 2009

Scientists identify new behavioral traits of immune cells; findings may help in understanding complex diseases

In diseases such as multiple sclerosis, cells of the immune system infiltrate the brain tissue, where they cause immense damage. For many years, it was an enigma as to how these cells can escape from the bloodstream. This is no trivial feat, given that specialized blood vessels act as a barrier between the nervous system and the bloodstream.

6 Nov 2009

Rice University's new BRC awarded $2M NIH grant to develop an inexpensive test for oral cancer

The National Institutes of Health (NIH) has awarded researchers in Rice University's new BioScience Research Collaborative (BRC) a $2 million Grand Opportunity (GO) grant to develop a fast, inexpensive test for oral cancer that a dentist could perform simply by using a brush to collect a small sample of cells from a patient's mouth.

6 Nov 2009

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer.

5 Nov 2009

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

Amgen today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.

5 Nov 2009

FDA clears ARKRAY's new GLUCOCARD Vital blood glucose monitoring system

ARKRAY, Inc., the world's 5th largest manufacturer of diabetes self-monitoring systems, today announced that it has received 510(k) clearance from the US Food and Drug Administration for its new GLUCOCARD Vital blood glucose monitoring system.

5 Nov 2009

Medical Condition News

CPEX Pharmaceuticals to feature Nasulin at the Diabetes Technology Meeting

Gene therapy saves two children with adrenoleukodystrophy

Physical education plays a key role for low-income communities in curbing obesity and improving fitness

Autism Consortium holds its fourth annual symposium to update on autism

Boosting NAD+ after spinal cord injury may prevent permanent nerve death

TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

FDA grants orphan drug designation for Sunesis Pharmaceuticals' voreloxin

Successful leukemia treatment with a radiolabeled antibody followed by stem cell transplant

Soda and other sugar-sweetened beverages linked to obesity; soda industry fails to acquit itself in landmark hearings

Revised Management Guidelines for diagnosing and treating thyroid cancer released

AcuFocus Corneal Inlay: Will it improve near vision in patients with presbyopia?

Declining kidney function linked to higher risk of heart failure in individuals with or without kidney disease

Exposure to higher levels of air pollution increases infants' risk for bronchiolitis

Prevalence of lactose intolerance may be far lower than previously estimated, says study

Higher levels of phosphorus in blood linked to increased calcification of coronary arteries, says study

Scientists identify new behavioral traits of immune cells; findings may help in understanding complex diseases

Rice University's new BRC awarded $2M NIH grant to develop an inexpensive test for oral cancer

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

Amgen announces the results for Phase 3 PRIME '203' trial of Vectibix

FDA clears ARKRAY's new GLUCOCARD Vital blood glucose monitoring system

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News